Azitra, Inc. (AZTR)
NYSEAMERICAN: AZTR · Real-Time Price · USD
0.1529
+0.0059 (4.01%)
At close: Aug 13, 2025, 4:00 PM
0.1445
-0.0084 (-5.49%)
Pre-market: Aug 14, 2025, 8:59 AM EDT
Azitra Revenue
In the year 2024, Azitra had annual revenue of $7.50K, down -98.91%.
Revenue (ttm)
$7.50K
Revenue Growth
-98.91%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
12
Market Cap
2.63M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.50K | -678.50K | -98.91% |
| Dec 31, 2023 | 686.00K | 402.00K | 141.55% |
| Dec 31, 2022 | 284.00K | 174.00K | 158.18% |
| Dec 31, 2021 | 110.00K | -315.00K | -74.12% |
| Dec 31, 2020 | 425.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
AZTR News
- 2 days ago - Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates - PRNewsWire
- 2 days ago - Azitra, Inc. Announces Reverse Stock Split - PRNewsWire
- 2 months ago - Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome - PRNewsWire
- 2 months ago - Azitra, Inc. Announces Presentation at the 2025 BIO International Convention - PRNewsWire
- 2 months ago - Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash - PRNewsWire
- 3 months ago - Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash - PRNewsWire
- 3 months ago - Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates - PRNewsWire
- 3 months ago - Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025 - PRNewsWire